文献速递白血病

人T细胞急性淋巴细胞白血病对Notch抑制的耐药机制及联合治疗

Resistance mechanism to Notch inhibition and combination therapy in human T-cell acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2023-01-01

该研究通过全基因组CRISPR-Cas9筛选,在人T细胞急性淋巴细胞白血病(T-ALL)中鉴定出PIK3R1缺失导致对Notch抑制剂耐药,其机制涉及PI3K/AKT信号增强并调控细胞周期与剪接体。同时发现CDK4/6与NOTCH同时靶向的联合方案在T-ALL异种移植模型中最为有效。

要点

  • PIK3R1突变缺失导致T-ALL对Notch抑制耐药,伴PI3K/AKT信号增强。
  • PIK3R1缺陷在转录和翻译后水平调控细胞周期与剪接体机器。
  • 同时靶向CDK4/6和NOTCH的联合方案在T-ALL异种移植模型中最为有效。

核心结论

  • PIK3R1缺失通过增强PI3K/AKT信号导致T-ALL对Notch抑制耐药。
  • 同时靶向CDK4/6和NOTCH的联合治疗在T-ALL异种移植模型中最为有效。

研究设计与样本

  • 研究采用全基因组CRISPR-Cas9筛选,在人T-ALL中鉴定对Notch抑制剂的耐药机制及新型靶向联合疗法。
  • 研究在T-ALL异种移植模型中评估联合治疗方案的效果。

主要发现

  • 磷酸肌醇-3-激酶调节亚基1(PIK3R1)突变缺失导致对Notch抑制耐药。
  • PIK3R1缺陷导致PI3K/AKT信号增强,在转录和翻译后水平调控细胞周期和剪接体机器。
  • 同时靶向细胞周期蛋白依赖性激酶4和6(CDK4/6)与NOTCH的联合方案在T-ALL异种移植模型中最为有效。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gain-of-function mutations in NOTCH1 are among the most frequent genetic alterations in T-cell acute lymphoblastic leukemia (T-ALL), highlighting the Notch signaling pathway as a promising therapeutic target for personalized medicine. Yet, a major limitation for long-term success of targeted therapy is relapse due to tumor heterogeneity or acquired resistance. Thus, we performed a genome-wide CRISPR-Cas9 screen to identify prospective resistance mechanisms to pharmacological NOTCH inhibitors and novel targeted combination therapies to efficiently combat T-ALL. Mutational loss of phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) causes resistance to Notch inhibition. PIK3R1 deficiency leads to increased PI3K/AKT signaling, which regulates cell cycle and the spliceosome machinery, both at the transcriptional and posttranslational level. Moreover, several therapeutic combinations have been identified, in which simultaneous targeting of the cyclin-dependent kinases 4 and 6 (CDK4/6) and NOTCH proved to be the most efficacious in T-ALL xenotransplantation models.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Cao L, Ruiz Buendía GA, Fournier N, et al. Resistance mechanism to Notch inhibition and combination therapy in human T-cell acute lymphoblastic leukemia. Blood Adv. 2023. PMID: 37358480. doi:10.1182/bloodadvances.2023010380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。